Primary Peptides, Inc.
PrivateLast Round
Series A
Feb 1, 2025
Est. Valuation
$75M
Total Funding Raised
$229,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Primary Peptides, Inc. operates in Healthcare & Life Sciences and is based in Vancouver. Its latest recorded funding round was a Grant round in May 2023.
Primary Peptides, Inc. is a biotechnology company that develops novel peptide therapeutics for neurological and cardiovascular diseases using protein manipulation technologies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Primary Peptides, Inc. Comparables
Compare Primary Peptides, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Argenica Therapeutics | 83% | |
| Axoltis Pharma | 82% | |
| Infensa Bioscience | 79% |
For institutional investors. Book with your work email.
Primary Peptides, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 1, 2025 | ||||
| Grant | May 1, 2023 | ||||
| Grant | May 2, 2022 |
For institutional investors. Book with your work email.
Primary Peptides, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Research Council of Canada | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 413% MoM.
- May 15, 2026
Monthly visitors increased 435% MoM.
For institutional investors. Book with your work email.
Primary Peptides, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Primary Peptides, Inc.'s valuation, stock price, and market status.
Is Primary Peptides, Inc. a public or private company?
Primary Peptides, Inc. is a private company.
What is the current stock price of Primary Peptides, Inc.?
Primary Peptides, Inc. is a private company, so its shares have no public market price. Caplight tracks Primary Peptides, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Primary Peptides, Inc. worth (valuation)?
Primary Peptides, Inc.'s valuation is estimated at $75.0M based on funding round data.
Can I buy Primary Peptides, Inc. stock?
Primary Peptides, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Primary Peptides, Inc.'s last funding round?
Primary Peptides, Inc.'s most recent funding round was Series A on February 1, 2025.
Who are the main investors in Primary Peptides, Inc.?
Key investors in Primary Peptides, Inc. include National Research Council of Canada.
Will Primary Peptides, Inc. IPO soon?
No public IPO plans have been announced for Primary Peptides, Inc..
How can I track Primary Peptides, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Primary Peptides, Inc.'s shares on secondary markets.